Almirall starts the year with solid growth
The first quarter was a good one for Almirall, and the new CEO hopes to live up to the 2021 guidance with the help of two potential EU approvals.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
During the first three months of the year, Almirall has generated EUR 215m in sales, although only a small portion of this was in the dermatology business, where Almirall competes with Leo Pharma.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
MC2 Therapeutics aims to lead psoriasis market
For subscribers
Leo Pharma struggles with lawsuit in the US
For subscribers
.jpg&w=384&q=75)
